Mark S. Forman

Rockefeller University — United States

Medicine · Health Sciences

51h-index13.0kcitations120works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(53), Parkinson's Disease Mechanisms and Treatments(33), Amyotrophic Lateral Sclerosis Research(25), Cholinesterase and Neurodegenerative Diseases(16), Computational Drug Discovery Methods(15)

Publications120 total

B Cell Activation: The Regulation by T Cells and the Induction of the Protein Tyrosine Kinase SYK
Digital Commons - RU (Rockefeller University)·2025Open Access
Early transgene expression of GALC enzyme in a phase I/II safety, tolerability and efficacy study of PBKR03 in infants with early infantile Krabbe disease (EIKD) (GALax-C)
Molecular Genetics and Metabolism·2023
Updated interim safety, biomarker, and efficacy data from Imagine-1: A phase 1/2 open-label, multicenter study to assess the safety, tolerability, and efficacy of a single dose, intra-cisterna magna (ICM) administration of PBGM01 in subjects with type I (early onset) and type IIA (late onset) infantile GM1 gangliosidosis (GM1)
Molecular Genetics and Metabolism·2023
Validation of a Suite of ERP and QEEG Biomarkers in a Pre-Competitive, Industry-Led Study in Subjects with Schizophrenia and Healthy Volunteers
SSRN Electronic Journal·2022· 5 citedOpen Access
Palatability and Swallowability of Pimavanserin When Mixed with Selected Food Vehicles: An Exploratory Open-Label Crossover Study
Geriatrics·2021· 4 citedOpen Access
P213 - A priori prediction of CYP3A victim drug-drug interaction of MK-1 and diltiazem using physiologically-based pharmacokinetic modeling (PBPK): qualification using clinical data
Drug Metabolism and Pharmacokinetics·2020
P2‐002: AN INTEGRATED MECHANISTIC AMYLOID PATHWAY MODEL INFORMED BY CLINICAL BIOMARKER DATA FROM VERUBECESTAT AND OTHER BACE INHIBITORS
Alzheimer s & Dementia·2019
Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (<scp>MK</scp>‐8931) in Healthy Elderly Male and Female Subjects
Clinical and Translational Science·2019· 17 citedOpen Access
Pharmacokinetics and Pharmacodynamics of the <scp>BACE</scp>1 Inhibitor Verubecestat (<scp>MK</scp>‐8931) in Healthy Japanese Adults: A Randomized, Placebo‐Controlled Study
Clinical Pharmacology & Therapeutics·2018· 20 cited
Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with <sup>18</sup>F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles
Journal of Nuclear Medicine·2018· 110 citedOpen Access
[O2–09–01]: ACUTE ADMINISTRATION OF A BACE INHIBITOR IN HEALTHY HUMANS RESULTS IN A SIGNIFICANT REDUCTION OF Aβ OLIGOMERS IN CEREBROSPINAL FLUID
Alzheimer s & Dementia·2017Open Access
POTENTIAL THERAPEUTIC BENEFITS OF DECREASING Aβ PRODUCTION THROUGH BACE INHIBITION
Innovation in Aging·2017Open Access
Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development.
2017
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease
Journal of Medicinal Chemistry·2016· 161 citedOpen Access
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
Science Translational Medicine·2016· 407 cited
Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma
CPT Pharmacometrics & Systems Pharmacology·2016· 25 citedOpen Access
Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development
Alzheimer s & Dementia Translational Research & Clinical Interventions·2016· 147 citedOpen Access
O2‐13‐04: Early Clinical Results and Preclinical Validation of the O‐Glcnacase (OGA) Inhibitor Mk‐8719 as a Novel Therapeutic for the Treatment of Tauopathies
Alzheimer s & Dementia·2016· 23 cited
P1‐107: Is the Peripheral Sink Hypothesis Physiologically Feasible? Evidence from Model‐Based Assessment of the Amyloid Pathway
Alzheimer s & Dementia·2016· 2 cited
P2‐005: Evidence from Model‐Based Assessments of Compounds Tested in Completed Clinical Trials Indicates That The Amyloid Hypothesis Has Not Been Adequately Tested
Alzheimer s & Dementia·2016
page 1 of 6Next →

Frequent Co-authors

John Q. Trojanowski(32), Virginia M.‐Y. Lee(24), Manuela Neumann(10), Bruce L. Miller(8), Christopher M. Clark(7), Murray Grossman(7), Linda K. Kwong(6), Julene K. Johnson(6), Nigel J. Cairns(5), Hans A. Kretzschmar(5), Howard I. Hurtig(5), Bin Zhang(5), Ian R. Mackenzie(4), Howard J. Rosen(4), Vivianna M. Van Deerlin(4), Susan Leight(4), Virginia Kimonis(4), Lauren Massimo(4), Elisabeth McCarty Wood(4), Deepa V. Dabir(4)